

Haitong International Invests in US Cellular Immunotherapy Company TCR2 Therapeutics

Hong Kong, 21 March, 2018 – Haitong International Securities Group (665.HK) announced that its private equity investment division has participated in the Round B financing of TCR2 Therapeutics, an innovative company in cellular immunotherapy in the United States, becoming the only Chinese brokerage participated in the financing. Leading investment parties include 6 Dimensions Capital, a subsidiary of WuXi AppTec, and US PE firm Curative Ventures. Among other investors include Haitong International, Redmile, Syno Capital, Hillhouse Capital, Leerink, Alexandria Venture, Mirae, and ArrowMark. Previous investors MPM Capital, F2 Ventures, and Cathay Fortune Capital also participated in this round of financing.

Headquartered in the heart of Kendall Square in Cambridge, TCR2 Therapeutics was founded in 2015 by renowned German immunologist Dr. Patrick Baeuerle with the vision of developing a novel T cell therapy approach. TCR2's TRuC™ platform is unique in recruiting the entire T cell receptor without HLA matching, helping to address the broadest population of patients with haematological malignancies and solid tumours.

Currently, TCR2 has established partnerships with several research institutes, including the Massachusetts General Hospital, the affiliated hospital of Ludwig Maximilian University of Munich, and the University of Freiburg.

“Management at TCR2 has more than 20 years of experience in the medical field. TCR2 has delivered impressive results in terms of efficacy, durability, and safety in preclinical models, and also has breakthroughs in allogeneic treatment. In recent years, cell immunotherapy is an innovative technology that is strongly supported by the biotechnology field in China and the United States, and is eligible for FDA and CFDA fast-track qualifications. Previously, Novartis and Kite's CAR-T therapy has brought a major breakthrough in the treatment of cancers such as leukaemia. We expect that TCR2's technology can achieve further breakthroughs in solid tumours and bring hope to cancer patients,” said Deng Xi, Managing Director of PE investment division of Haitong International.

“Biomedical is one of key areas that Haitong International's PE Investment division focuses on. The Stock Exchange of Hong Kong is expected to issue new listing rules for biotech companies. It is expected that the new regulations will create a good capital platform for more biotech companies and bring new investment opportunities to the capital market. We hope to achieve a win-win situation of witnessing a rapid growth at the invested companies through equity investments,” said Sun Tong, Executive Committee Member and CIO of Haitong International.

Since establishment in 2017, Haitong International's PE investment division has aimed at tapping into various kinds of USD investment projects in Hong Kong or in the U.S. that are related to China and are at PE or VC stages with focus on industries including consumption, Internet technology, as well as medical and health care. In 2017, Haitong International invested in three education projects in China, including Puxin Education & Technology Group Co Ltd. Going forward, Haitong International will continue to focus on high-growth industries such as medical care, high technology, and consumption in China and US.

– END –

Haitong International Securities Group Limited

Haitong International Securities Group Limited (“Haitong International”; Stock Code: 665.HK) is an international financial institution with established presence in Hong Kong and a rapidly expanding network across the globe. It strives to serve as a bridge linking up the Chinese and overseas capital markets. The parent company of Haitong International is Haitong Securities Co. Ltd (“Haitong Securities”, Stock Code: 600837.SH; 6837.HK).

To date, Haitong International has well positioned to serve about 200,000 corporate, institutional, as well as retail and high-net worth clients worldwide. Its well established investment banking business platform provides corporate finance, wealth management, asset management, institutional clients (key businesses include fixed income, currency and commodities (FICC), derivatives, institutional equities) and investments business, and a full spectrum of financial products and services. Haitong International possesses a sound risk management system that is in line with international standards. The company have been assigned a “Baa2” long-term issuer rating by Moody’s and a “BBB” long-term credit rating by Standard and Poor’s. Haitong International has a global financial servicing network covering the world’s major capital markets including Hong Kong, Singapore, New York, London, Tokyo, Mumbai and Sydney, thereby making us to be a leading global financial institution with international competitiveness, systematic importance and brand influence.

For further information, please contact:

Haitong International Securities Group Limited

Theresa Tang
Tel : (852) 2213 8508
Email: theresa.y.s.tang@htisec.com

Sarah Yan
Tel : (852) 2213 8588
Email: sarah.th.yan@htisec.com